Jacobs Levy Equity Management’s Spyre Therapeutics SYRE Stock Holding History

Jacobs Levy Equity Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17,447	Closed	-$1M	–	1085
2022 Q1	$1M	Buy	17,447 +11,683	+203%	+$981K	0.01%	753
2021 Q4	$684K	Buy	+5,764	New	+$910K	﹤0.01%	792
2021 Q3	–	Sell	-2,372	Closed	-$413K	–	1126
2021 Q2	$413K	Sell	2,372 -5,205	-69%	-$946K	﹤0.01%	899
2021 Q1	$1.5M	Buy	7,577 +2,926	+63%	+$561K	0.01%	651
2020 Q4	$915K	Sell	4,651 -5,008	-52%	-$1.04M	0.01%	744
2020 Q3	$1.71M	Buy	+9,659	New	+$1.79M	0.02%	547
2020 Q2	–	Sell	-1,596	Closed	-$186K	–	1151
2020 Q1	$186K	Buy	+1,596	New	+$271K	﹤0.01%	897
2019 Q3	–	Sell	-1,914	Closed	-$328K	–	995
2019 Q2	$328K	Buy	+1,914	New	+$331K	﹤0.01%	804
2018 Q3	–	Sell	-535	Closed	-$142K	–	1069
2018 Q2	$142K	Buy	+535	New	+$132K	﹤0.01%	980
2018 Q1	–	Sell	-628	Closed	-$85K	–	1061
2017 Q4	$85K	Buy	+628	New	+$76.8K	﹤0.01%	958

Other funds holding SYRE

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management's SYRE Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Spyre Therapeutics (SYRE) in Q2 2022, closing a stake of 17,447 shares — an estimated $1M sold.

Jacobs Levy Equity Management first reported a position in SYRE in Q4 2017 and held it in 10 quarters. The position peaked at $1.71M in Q3 2020. 66 funds tracked by Wall St. Rank hold SYRE as of Q2 2022.

Jacobs Levy Equity Management reported no remaining Spyre Therapeutics position as of Q2 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 17,447 Spyre Therapeutics shares in Q2 2022, an estimated $1M.
Jacobs Levy Equity Management first reported a position in Spyre Therapeutics in Q4 2017 and held it in 10 quarters.
Jacobs Levy Equity Management's Spyre Therapeutics position peaked at $1.71M in Q3 2020.
66 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.